Most lung lesions found on CT scans turn out to be benign. The term “lung lesion” covers everything from a tiny spot left behind by an old infection to a cancerous tumor, and the overwhelming majority of small nodules discovered incidentally will never threaten your health. That said, every lesion needs some level of evaluation, because the small percentage that are malignant look a lot like the harmless ones on initial imaging. Understanding what your doctors are looking for and what the follow-up process involves can take real weight off your shoulders during what is often an anxious wait.
What Counts as a Lung Lesion
Doctors use “lung lesion” as a catch-all for any abnormal area visible on a chest X-ray or CT scan. In practice, the most common finding is a pulmonary nodule, a roughly round spot smaller than 3 centimeters across. Anything larger than 3 centimeters is usually called a mass, and masses carry a higher suspicion for cancer simply because of their size. Lesions can also appear as ground-glass opacities (hazy patches that do not completely block the lung tissue behind them), cavitary lesions (spots with a hollow center), or areas of consolidation that look like pneumonia. Each pattern gives radiologists different clues about whether the cause is likely infectious, inflammatory, or neoplastic.
Common Benign Causes
Infections are responsible for a large share of lung lesions. A healed bout of pneumonia, tuberculosis, or a fungal infection like histoplasmosis can leave behind a small scar or granuloma that shows up years later when you get a CT for an unrelated reason. Histoplasmosis in particular is a well-known mimic of lung cancer: it produces granulomatous lesions that can look like a solid tumor on imaging, and in endemic regions it is a frequent source of diagnostic confusion.1PubMed Central. Pulmonary Histoplasmosis: A Clinical Update Other infections, including aspergillosis and actinomycosis, can form pseudo-tumoral lesions that are difficult to distinguish from primary lung cancer without tissue sampling.2PubMed. Case 6: Pulmonary histoplasmosis presenting as a pseudo-tumoral lesion
Non-infectious inflammatory conditions add to the list. Sarcoidosis produces clusters of granulomas in the lungs, and rarer entities like cholesterol granuloma can appear as an asymptomatic lung and pleural lesion that initially raises concern for tuberculosis or malignancy but turns out to be entirely benign on biopsy.3PubMed Central. Cholesterol Granuloma: An Underrecognized Cause of Benign Lung Granuloma Rheumatoid nodules, organizing pneumonia, and other autoimmune-related processes round out the inflammatory category.
Among benign tumors, hamartomas are by far the most common. These are slow-growing collections of cartilage, fat, and connective tissue. When a hamartoma shows “popcorn” calcification or visible fat on CT, a radiologist can often make the diagnosis without any biopsy at all.4Chest Imaging. Hamartoma and Benign Tumor-like Lesions Other benign lung tumors like lipomas and chondromas exist but are quite rare.
When a Lesion Might Be Cancer
Certain features raise concern. Larger size is the most straightforward: a nodule over 8 millimeters gets more scrutiny than one under 6 millimeters, and anything over 3 centimeters is treated with high suspicion. Irregular or spiculated (spiky) edges, an upper-lobe location, and growth over time all increase the probability of malignancy. Your personal history matters too. A current or former smoker over 50 with a new spiculated nodule faces a very different risk profile than a 30-year-old nonsmoker with a smooth, calcified spot.
Primary lung cancers, most commonly adenocarcinoma and squamous cell carcinoma, are the main malignant concern. Less often, a lung lesion turns out to be a metastasis from a cancer elsewhere in the body, such as the colon, breast, or kidney. In children the calculus flips: benign causes dominate even more strongly, and when malignancy does occur it is almost always a metastasis rather than a primary lung cancer.5PubMed Central. Pediatric pulmonary nodules: current state of knowledge, AI applications, and future directions
How Doctors Estimate Risk
Rather than simply eyeballing a scan, clinicians often feed nodule characteristics into validated risk-prediction models. The Brock model (also called the PanCan model) is one of the most widely studied. A large meta-analysis pooling data from over 85,000 patients found that the Brock model correctly distinguished benign from malignant nodules with a pooled accuracy (measured by area under the curve) of about 0.80, with sensitivity around 82% and specificity around 80%. It performed especially well for small nodules in the 1-to-8-millimeter range, where accuracy climbed considerably.6PubMed. Pulmonary nodule malignancy probability: a meta-analysis of the Brock model Other models like the Mayo Clinic calculator and the Herder model take slightly different inputs. When these were compared head-to-head in one study, they performed similarly to each other, with none showing a clear statistical edge.7PubMed Central. Comparison of Brock University, Mayo Clinic and Herder models for pretest probability of cancer in solid pulmonary nodules
Researchers have experimented with combining multiple models to improve accuracy. One effort that merged the Brock, Mayo, and a Chinese hospital-derived model achieved an area under the curve of about 0.87 and was able to stratify nodules into low-, medium-, and high-risk categories with malignancy rates ranging from roughly 3% to over 60%.8Holistic Integrative Oncology. Enhancing lung cancer screening and management: a combined model for elevating malignant risk prediction of solitary pulmonary nodules by integrating the brock, mayo, and PKUPH models These tools are not perfect, but they give your doctor a structured way to decide whether your nodule warrants aggressive workup or patient monitoring.
Surveillance and the Fleischner Guidelines
For many small, low-risk nodules, the recommended next step is simply to watch and wait. The Fleischner Society, an international group of thoracic radiologists and pulmonologists, publishes guidelines that most hospitals follow. The 2017 revision raised the minimum size threshold for routine follow-up, meaning that very small nodules in low-risk patients may not need any additional imaging at all. For nodules that do warrant monitoring, the guidelines give a range of follow-up intervals rather than a single fixed date, so doctors and patients can factor in individual circumstances.9PubMed. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017 The aim is to reduce unnecessary scans while still catching any nodule that starts to grow.
The guidelines specifically target nodules found incidentally, meaning outside a formal lung cancer screening program. Screening programs for high-risk individuals (typically long-term smokers over 50) follow a separate protocol, usually Lung-RADS, which has its own size and risk thresholds. These Fleischner recommendations are meant to cut down on the cascade of scans, biopsies, and anxiety that can follow a tiny finding on an unrelated CT.10Digital Diagnostics. Use of Fleischner Society criteria for assessment of pulmonary nodules on computed tomography: practice guidelines
Ground-Glass Nodules Deserve Their Own Conversation
Not all nodules are solid. Ground-glass nodules (GGNs) appear as hazy, translucent areas on CT, and they play by somewhat different rules. A pure ground-glass nodule is more likely to represent a pre-invasive or minimally invasive form of adenocarcinoma, which tends to be extremely slow growing. Many pure GGNs show no change in size over two or more years.11PubMed Central. ACR Appropriateness Criteria® Indolent Lung Cancer The danger signal is when a ground-glass nodule develops a solid component or increases in density, because that suggests the lesion is becoming more invasive.
Management guidelines call for biopsy or surgical resection of pure GGNs that grow or develop a solid part, pure GGNs larger than about 10 to 15 millimeters that persist, and part-solid nodules whose solid component exceeds roughly 6 millimeters.12PubMed Central. Guidelines for the Investigation and Management of Ground Glass Nodules Stable pure GGNs below those thresholds can often be monitored with periodic CT scans over several years. The key point for patients is that a ground-glass finding, while it can technically represent early cancer, usually behaves so indolently that a careful watch-and-wait strategy is safe and appropriate.
PET Scans and Their Limits
When a nodule is large enough or suspicious enough to justify more than surveillance, doctors often order a PET/CT scan. This test uses a radioactive sugar tracer (FDG) to highlight areas of high metabolic activity, which cancers tend to have. A well-designed comparison found that PET had a sensitivity of about 92% and a specificity of about 82% for characterizing solitary pulmonary nodules, outperforming CT alone, which had high sensitivity but much lower specificity.13Journal of Nuclear Medicine. A Comparison of the Diagnostic Accuracy of 18F-FDG PET and CT in the Characterization of Solitary Pulmonary Nodules In other words, PET is better at correctly identifying which nodules are benign, reducing unnecessary biopsies.
There is an important caveat. In regions where infectious lung diseases like tuberculosis and histoplasmosis are common, PET specificity drops substantially. A meta-analysis found that in areas endemic for such infections, average specificity fell to around 61%, compared with about 77% in non-endemic areas.14JAMA. Accuracy of FDG-PET to Diagnose Lung Cancer in Areas With Infectious Lung Disease: A Meta-analysis Active granulomas and inflamed tissue gobble up the tracer just like tumors do, leading to false positives. If you live in, say, the Ohio River Valley in the United States or other histoplasmosis-endemic areas, your doctor should factor that geography into how they interpret a positive PET result. Newer molecular tracers beyond FDG are being investigated that may add complementary information for tricky cases.15PubMed. Molecular imaging of pulmonary nodules
When You Need a Biopsy
If imaging cannot settle the question, tissue sampling becomes necessary. The traditional workhorse is a CT-guided transthoracic needle biopsy, where a radiologist inserts a needle through the chest wall into the nodule under CT guidance. This approach has strong diagnostic accuracy, generally around 90% for larger nodules and somewhat lower for nodules under about 1.5 centimeters. The main downside is the complication rate: roughly 15 to 25% of patients develop a pneumothorax (a partially collapsed lung), with about 7% needing a chest tube and hospitalization.16CHEST Pulmonology. Protocol and Rationale for the Navigation Endoscopy to Reach Indeterminate Lung Nodules vs Transthoracic Needle Aspiration (VERITAS) Randomized Controlled Trial
Navigational bronchoscopy offers an alternative with a considerably gentler safety profile. Instead of going through the chest wall, a flexible scope is guided through the airways to reach the nodule from inside the lung. A randomized trial comparing navigational bronchoscopy with transthoracic biopsy found that bronchoscopy achieved a specific diagnosis in about 79% of cases versus about 74% for the needle approach, meeting the bar for non-inferiority. The pneumothorax rate, however, was dramatically lower: roughly 3% with bronchoscopy compared with about 35% with the needle, and chest tube placement dropped from about 14% to under 1%.17PubMed Central. Navigational Bronchoscopy versus Transthoracic Biopsy for Lung Nodules Robotic-assisted bronchoscopy, a newer refinement, appears to match the diagnostic yield of transthoracic biopsy while cutting the rate of pneumothorax requiring intervention by about three-quarters.18PubMed Central. Robotic-assisted transbronchial biopsy versus computed tomography–guided transthoracic needle biopsy for peripheral pulmonary lesions: a systematic review and meta-analysis of direct comparative studies
These developments matter for you as a patient because they expand the options your medical team can offer. If your nodule sits deep in the periphery of the lung, transthoracic needle biopsy may still be the better choice. If it is reachable through the airways, or if you have a condition that makes pneumothorax especially risky, bronchoscopic approaches give you a safer route to a diagnosis.
Treatment When a Lesion Turns Out to Be Cancer
For early-stage non-small cell lung cancer, the two leading treatments are surgical resection and stereotactic body radiation therapy (SBRT). Current evidence favors surgery for patients who are healthy enough to undergo the operation. One study found unadjusted two-year overall survival rates of about 90% for surgical patients compared with about 79% for SBRT, with recurrence-free survival also higher in the surgery group.19PubMed Central. Clinical, Quality, and Cost Outcomes of Patients With Early-Stage Non-Small Cell Lung Cancer Undergoing Surgery or Stereotactic Body Radiation Therapy A separate study comparing the two found that five-year overall survival was 58% after surgery and 49% after SBRT, though the SBRT group carried a heavier burden of other health problems, making a direct comparison tricky.20PubMed Central. Comparison of prognosis between patients undergoing surgical resection and stereotactic ablative radiotherapy for early-stage lung cancer
For patients who are not fit for surgery due to advanced age, poor lung function, or other serious medical conditions, SBRT is considered the standard of care and delivers meaningful local tumor control with minimal recovery time.21PubMed Central. Current evidence and ongoing trials for surgery versus stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer: a narrative review The encouraging takeaway is that early-stage lung cancers caught as small nodules are highly treatable regardless of which approach is used.
The Emotional Weight of a Finding
What the medical literature sometimes undersells is just how stressful it is to be told you have a “spot” on your lung. In one study, about 60% of patients with a pulmonary nodule reported worrying about it at least once a month, and roughly one in five worried every day.22PubMed Central. Effect of a pulmonary nodule fact sheet on patient anxiety and knowledge: a quality improvement initiative A cross-sectional study of Chinese patients found that nearly three-quarters reported moderate or high levels of distress after learning about an incidental nodule.23Scientific Reports. Distress and its influencing factors among Chinese patients with incidental pulmonary nodules: a cross-sectional study
A trial called Watch the Spot found that about a third of patients experienced at least mild distress, with roughly 7% meeting criteria for severe distress. Distress tended to be worse for people with larger nodules, younger patients, women, smokers, and Black and Hispanic individuals. One of the strongest predictors of both distress and anxiety was not being notified about the finding promptly by a clinician.24PubMed. Emotional Distress, Anxiety, and General Health Status in Patients With Newly Identified Small Pulmonary Nodules: Results From the Watch the Spot Trial That last detail is actionable: if you find out about a nodule from a patient portal before your doctor calls, the anxiety spike is real and measurable. Ask your care team to walk you through what the finding means rather than interpreting the radiology report yourself.
Research on shared decision-making suggests that most patients want to be actively involved in choices about their nodule management. In one systematic review, about 58% preferred shared decisions with their physician and another 24% preferred to make the decision themselves. Clinicians who practiced shared decision-making also reported feeling more comfortable managing nodules overall.25PubMed Central. Shared decision-making in the management of pulmonary nodules: a systematic review of quantitative and qualitative studies If you feel like your doctor is making decisions for you rather than with you, it is reasonable to ask for a clearer conversation about your options and the reasoning behind them.
Liquid Biopsies and Other Emerging Tools
The field is actively trying to develop less invasive ways to sort benign from malignant nodules. Liquid biopsy, which analyzes fragments of DNA or cells circulating in a blood draw, is one of the most promising directions. One early-stage test that combines blood-based biomarkers with CT imaging features achieved about 90% sensitivity and 64% specificity as a rule-out test for indeterminate nodules, meaning it was good at reassuring patients whose nodules were benign while still catching most cancers.26PubMed Central. A multivariate cell-based liquid biopsy for lung nodule risk stratification: Analytical validation and early clinical evaluation A separate assay using machine learning on cell-free DNA fragments reported sensitivity above 90% and specificity above 80% in early testing.27Cancer Research. Abstract 3448: A novel liquid biopsy lung cancer detection method using a coverage and fragment end motif machine learning analysis These tests are not yet routine, but they signal a future where a blood draw might spare you from an invasive biopsy or months of anxious surveillance scans.
Artificial intelligence is also reshaping how nodules are detected and classified. AI systems serving as a “second reader” alongside radiologists can achieve over 95% sensitivity for nodule detection on CT scans, with fewer than one false positive per scan on average.28PubMed Central. Artificial intelligence in automated detection of lung nodules: a narrative review AI-based diagnostic frameworks have also shown improved accuracy in classifying whether a detected nodule is likely benign or malignant, reducing the variability that comes from different radiologists reading the same scan differently.29PubMed Central. Establishing an AI-based diagnostic framework for pulmonary nodules in computed tomography More advanced radiomics models that extract dozens of quantitative features from CT images are performing well even for small nodules under 10 millimeters.30PubMed Central. Noninvasive differentiation of benign and malignant solid pulmonary nodules using multiparameter dual-layer spectral CT radiomics None of this replaces a physician’s judgment, but it does mean that the technical tools available to your care team are improving rapidly.
Occupational Exposures and Lung Lesions
If you work in mining, construction, manufacturing, or any industry involving chronic inhalation of dust or fumes, the calculus around lung lesions shifts. Silica exposure in particular can produce fibrotic changes and nodular patterns on imaging that look alarming but represent occupational lung disease rather than cancer. Research on workers exposed to silica nanoparticles has documented a specific pattern of airway remodeling and pulmonary fibrosis driven by the inflammatory response to inhaled particles.31PubMed Central. Deciphering Pathogenesis of Silica Nanoparticle-Induced Airway Remodeling and Fibrosis: Insights from a Human Patient Cohort and a Murine Model Asbestos exposure can cause pleural plaques and rounded atelectasis, both of which mimic more worrisome findings on CT. If you have a significant occupational history, make sure your radiologist and pulmonologist know about it, because it profoundly affects how a lung lesion should be interpreted and followed.